Últimas noticias sobre Amarin Corp (NASDAQ:AMRN) Bolsa

Amarin Corp

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Amarin Corp PLC

Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) today announced that Peter Fishman has been appointed as Chief Financial Officer for the Company, effective immediately. He will be responsible for leading Amarin's global finance organization and will report directly to the Company's Chief Executive Officer, Aaron Berg. Most recently, Mr. Fishman served as the Company's Global Controller and principal financial and accounting officer.

News

Management

AMRN

Amarin Appoints Peter Fishman CFO, Effective Immediately

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Silence Therapeutics PLC &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>)</h3>
<ul>
<li>On Nov. 14, Silence Therapeutics reported a quarterly loss of 75 cents per share, versus a year-ago loss of 9 cents per share The company reported $1.49 million in sales. &#8220;The Silence team is focused on continued execution across the business,&#8221; said Craig Tooman, President and Chief Executive Officer at Silence. &#8220;We look forward to presenting additional data from our wholly owned clinical programs at upcoming medical meetings and progressing our pipeline to bring innovative gene silencing medicines to patients around the world.&#8221; The company's stock fell around 37% over the past five days and has a <a href="https://www.benzinga.com/quote/SLN">52-week low of $9.22</a>.</li>
<li>RSI Value: 12.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>SLN Price Action: Shares of Silence Therapeutics fell 13.2% to close at $11.02 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1">latest SLN news.</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="823" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042649/image-187.png" alt="" class="wp-image-654486" style="width:787px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042649/image-187.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042649/image-187-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042649/image-187-768x693.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Terns Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>)&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Nov. 12, Terns Pharma posted a third-quarter loss of 28 cents per share, compared to market estimates for a loss of 34 cents per share. &#8220;Our progress in the third quarter was highlighted by the compelling topline results from our Phase 1 study of TERN-601, which demonstrated class-leading potential as a differentiated, once-daily, oral GLP-1R agonist for the treatment of obesity and supports its rapid advancement into Phase 2 studies,&#8221; stated Amy Burroughs, chief executive officer of Terns. The company's stock fell around 22% over the past five days and <a href="https://www.benzinga.com/quote/TERN">has a 52-week low</a> of $3.59.</li>
<li>RSI Value: 26.34</li>
<li>TERN Price Action: Shares of Terns Pharmaceuticals fell 7.6% to close at $5.70 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1">trend in TERN stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="920" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042754/image-188.png" alt="" class="wp-image-654492" style="width:667px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042754/image-188.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042754/image-188-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042754/image-188-768x695.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
<h3 class="wp-block-heading">Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>)</h3>
<ul>
<li>On Oct. 30, Amarin posted a quarterly loss of 6 cents per share, compared to market estimates of a loss of 5 cents per share. Aaron Berg, Amarin&#8217;s President and CEO stated, &#8220;While we and our global partners continue to execute on our multipronged global strategy focused on getting VASCEPA/VAZKEPA into the hands of as many patients as possible, the senior leadership team and I, as well as the Board of Directors, remain committed to evaluating all opportunities to maximize the value and impact of this highly impactful product. To that end, we look forward to highlighting the global opportunity for VASCEPA/VAZKEPA and to hear directly from both prescribers and select partners from around the world on the impact of VASCEPA/VAZKEPA during our upcoming virtual Analyst and Investor Day on November 14.&#8221; The company's stock fell around 16% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/AMRN">low of $0.46</a>.</li>
<li>RSI Value: 25.86</li>
<li>AMRN Price Action: Shares of Amarin fell 7% to close at $0.46 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1">breakout in AMRN shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="632" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042902/image-189.png" alt="" class="wp-image-654498" style="width:659px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042902/image-189.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042902/image-189-300x207.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19042902/image-189-768x529.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

TERN

Top 3 Health Care Stocks You'll Regret Missing In Q4

Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) today announced that investigators will present an additional subgroup analysis from the landmark REDUCE-IT outcomes trial in patients with and without coronary artery disease (CAD) history and mechanistic data on eicosapentaenoic acid (EPA) at the American Heart Association's Scientific Sessions, November 16-18, 2024 in Chicago, IL.
"The data to be presented at the AHA Scientific Sessions continues to affirm the clinical utility and value of VASCEPA&#xAE;/VAZKEPA&#xAE; (icosapent ethyl), not only in the overall REDUCE-IT trial population, but also across various subgroups analyzed to date," said Steve Ketchum, PhD, Chief Scientific Officer at Amarin. "Data presented at AHA will showcase new evidence from the REDUCE-IT CAD subanalysis, highlighting the benefits of VASCEPA/VAZKEPA in secondary prevention patients, with and without CAD history."
Dr. Ketchum further added, "Additional data to be featured at the AHA Scientific Sessions include research highlighting the mechanistic effects of EPA, particularly its antioxidant effects in endothelial cells and the ability of EPA to impact the oxidation of Lp(a) particles. High Lp(a) concentrations are associated with increased CV event risk, and people with high levels face a 2-4 times greater risk of having an early event. With about 20% of the global population affected, research is crucial for understanding and addressing elevated Lp(a)."

Biotech

General

Amarin Corporation Announces That Investigators Will Present An Additional Subgroup Analysis From The REDUCE-IT Outcomes Trial In Patients With And Without Coronary Artery Disease History And Mechanistic Data On Eicosapentaenoic Acid At The American Heart Association's Scientific Sessions

Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. The company reported quarterly sales of $42.300 million which missed the analyst consensus estimate of $44.510 million by 4.96 percent. This is a 35.96 percent decrease over sales of $66.056 million the same period last year.

Earnings

Earnings Misses

Amarin Corp Q3 2024 GAAP EPS $(0.06) Misses $(0.05) Estimate, Sales $42.300M Miss $44.510M Estimate

Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT&#xAE; cardiovascular outcomes trial with VASCEPA&#xAE;/VAZKEPA&#xAE; (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic&nbsp;acid (EPA) that will be presented at the European Society of Cardiology (ESC) Congress in London, United Kingdom, August 30 – September 2, 2024.
The accepted abstracts include a REDUCE-IT subgroup analysis to assess if baseline small dense low density lipoprotein cholesterol (sdLDL-C) modifies the effect of icosapent ethyl (IPE) on cardiovascular events. A second abstract examines the association of triglycerides with cardiovascular events in patients with initial or recurrent acute coronary syndrome (ACS). A third abstract estimates the number of ACS patients eligible for IPE in Spanish hospitals, and finally, a fourth abstract measures the effects of EPA on oxidation of Lp(a) under experimental conditions of high glucose.

Amarin Shares Latest Research Highlighting VASCEPA/VAZKEPA REDUCE-IT Subgroup Data And New Mechanistic Insights Into Eicosapentaenoic Acid To Be Presented At ESC Congress 2024

WIIM

Amarin shares are trading lower. The company reported Q2 financial results.

Guidance

Amarin Reiterates For FY24 It Believes That Current Cash And Investments And Other Assets Are Adequate To Support Continued Operations

Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.04) by 125 percent. The company reported quarterly sales of $67.500 million which beat the analyst consensus estimate of $51.019 million by 32.30 percent. This is a 15.80 percent decrease over sales of $80.167 million the same period last year.

Earnings Beats

Amarin Corp Q2 2024 Adj. EPS $0.01 Beats $(0.04) Estimate, Sales $67.500M Beat $51.019M Estimate

Under the terms of the PLA, Vascepa will be reimbursed as a Special Authority product by Alberta Health for the secondary prevention of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with established cardiovascular disease and elevated triglycerides.

Health Care

HLS Therapeutics Has Entered Into A Product Listing Agreement With The Province Of Alberta, For The Listing And Public Reimbursement Of Amarin's Vascepa (Icosapent Ethyl), Effective August 1, 2024

Amarin shares are trading higher after the company received national reimbursement for VAZKEPA in Portugal.

Portuguese Ministry Of Health Approves VAZKEPA For National Reimbursement To Reduce Cardiovascular Risk In High-Risk Patients; Eighth National Reimbursement In Europe; Amarin To Begin Commercialization In Portugal On August 1, 2024

Amarin's China Partner EddingPharm Receives Regulatory Approval From NMPA For VASCEPA In Mainland China For Cardiovascular Risk Reduction

Cantor Fitzgerald analyst Louise Chen reiterates Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) with a Overweight.

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Amarin Corp

Shares of Core &amp; Main Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNM#NYSE">CNM</a>) fell sharply during Tuesday's session after the company reported <a href="https://www.benzinga.com/quote/CNM/earnings">mixed first-quarter financial results.</a>
Core &amp; Main posted quarterly earnings of 49 cents per share, missing market expectations of 52 cents per share. The company's quarterly sales came in at $1.74 billion versus estimates of $1.72 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Core &amp; Main shares dipped 11.4% to $49.77 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>MicroAlgo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares jumped 284% to 5.99 after the company announced that it will jointly establish a micro-consciousness quantum research center with WiMi.</li>
<li>Sobr Safe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) surged 112% to $0.56 after the company announced SOBRsure device purchases from two new customers.</li>
<li>Annexon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) climbed 40% to $6.44 after the company&#8217;s Phase 3 trial of ANX005 met its primary endpoint.</li>
<li>WiMi Hologram Cloud Inc &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIMI#NASDAQ">WIMI</a>) shares gained 37.3% to $1.18 after the company announced that the company and MicroAlgo will jointly establish a micro-consciousness quantum research center.</li>
<li>Core Scientific Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) shares rose 29% to $6.28. Core Scientific announced the signing of a series of 12-year contracts with CoreWeave, the AI Hyperscaler.</li>
<li>Oblong Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) gained 25% to $0.32 after the company announced that it signed a non-binding letter of intent to acquire Dwellwell Analytics.</li>
<li>Captivision Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPT#NASDAQ">CAPT</a>) shares climbed 22.7% to $4.16 after dipping 28% on Monday.</li>
<li>Marin Software Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) gained 21.2% to $2.97. Marin Software announced expanded Amazon integration to unlock channel for all advertisers.</li>
<li>Moving Image Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#NYSE">MITQ</a>) gained 20.2% to $0.67.</li>
<li>Alset Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEI#NASDAQ">AEI</a>) shares climbed 19.4% to $1.23</li>
<li>CareCloud Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) shares gained 18.2% to $3.54.</li>
<li>Saia Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) shares climbed 12.3% to $452.00 after the company reported an 18% increase in LTL shipments per workday in April.</li>
<li>Terawulf Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) gained 12% to $2.30 after the company issued May 2024 production and operations update.</li>
<li>SINTX Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) gained 11.8% to $7.28.</li>
<li>Zai Lab Ltd – ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) shares rose 9.9% to $19.78.</li>
<li>Hillevax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) gained 9.7% to $13.60.</li>
<li>Agenus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) shares rose 9.3% to $18.55.</li>
<li>SkyWest Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYW#NASDAQ">SKYW</a>) gained 5.6% to $83.87.</li>
<li>Forward Air Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) gained 3.9% to $17.88.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>ENDRA Life Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares fell 66.4% to $0.073 after the company announced pricing of $8.0 million public offering.</li>
<li>Avalon Globocare Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALBT#NASDAQ">ALBT</a>) shares fell 30.9% to $0.85 after surging 317% on Monday.</li>
<li>Equillium Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) fell 25.2% to $1.10 after the company announced topline data from its Phase 2 study of EQ101 in alopecia areata.</li>
<li>JIADE Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) fell 21.3% to $9.81.</li>
<li>Designer Brands Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>) shares fell 20.5% to $8.79 following first-quarter earnings.</li>
<li>MingZhu Logistics Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>) shares fell 17.5% to $0.38. MingZhu Logistics Holdings shares jumped 32% on Monday after the company announced an agreement to acquire Oxylus Global.</li>
<li>Humacyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares declined 17.1% to $6.11.</li>
<li>NewGenIvf Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 16.8% to $1.15. On Monday, NewGenIvf signed a non-binding $617.34 million deal for potential reverse merger with pharma company COVIRIX.</li>
<li>GCT Semiconductor Holding Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCTS#NYSE">GCTS</a>) shares declined 14.6% to $3.92</li>
<li>CalAmp Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares declined 14% to $0.87. CalAmp recently entered into a restructuring support agreement to take the company private and has voluntarily initiated proceedings under Chapter 11 of the United States Bankruptcy Code.</li>
<li>Nuscale Power Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) shares fell 12.2% to $6.70.</li>
<li>Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) shares declined 12% to $0.75 after the company announced that it appointed Aaron Berg as President and CEO.</li>
<li>Cibus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) shares declined 11.4% to $11.76.</li>
<li>Ivanhoe Electric Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IE#NYSE">IE</a>) shares fell 10% to $9.73.</li>
<li>Bath &amp; Body Works Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) fell 10.5% to $46.39 after the company reported first-quarter earnings.</li>
<li>ICICI Bank Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBN#NYSE">IBN</a>) shares declined 10.4% to $25.38 as Indian stocks moved lower amid early results from India&#8217;s general election.</li>
<li>Microbot Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) shares fell 9.4% to $1.25 after jumping 38% on Monday.</li>
<li>Bark Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BARK#NYSE">BARK</a>) shares declined 9.3% to $1.27 after the company reported downbeat financial results for its fourth quarter and issued FY25 revenue guidance below estimates.</li>
<li>HDFC Bank Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HDB#NYSE">HDB</a>) declined 9.2% to $55.62 as Indian stocks moved lower amid early results from India&#8217;s general election.</li>
<li>Hywin Holdings Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYW#NASDAQ">HYW</a>) shares fell 9% to $0.61 after jumping 91% on Monday.</li>
<li>Axos Financial Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) shares fell 8.9% to $47.79 after Short seller Hindenburg Research issued a short report on the stock.</li>
<li>Modine Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) shares fell 8.7% to $91.14.</li>
<li>Arch Resources Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCH#NYSE">ARCH</a>) shares declined 8.4% to $164.81.</li>
<li>Dave Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) fell 7.5% to $35.05. Dave announced an extension of its official partnership with the Drew League, Los Angeles&#8217; premiere Pro-Am basketball league.</li>
<li>GameStop Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares fell 5.5% to $26.45, pulling back after rallying 21% on Monday.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/06/39157476/nvidia-to-rally-around-11-here-are-10-top-analyst-forecasts-for-tuesday">Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday</a>

Intraday Update

Movers

AGEN

ALBT

ANNX

ARCH

BARK

BBWI

CAMP

CAPT

CBUS

CCLD

Core Scientific, Inc. - Class A Common Stock

CORZ

DAVE

FWRD

GCTS

HLVX

HUMA

JDZG

MBOT

MITQ

MLGO

MRIN

NDRA

NIVF

OBLG

SAIA

SINT

SKYW

SOBR

WIMI

WULF

YGMZ

ZLAB

Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Amarin shares are trading lower after the company announced that it appointed Aaron Berg as President and CEO.

Amarin Has Appointed Aaron Berg, Currently Amarin's Executive Vice President And President Of The US Business, As President And Chief Executive Officer, Following The Resignation Of Patrick Holt As President & CEO Of The Company

Amarin Corporation Announces Greek Ministry Of Health Approval For National Reimbursement Of VAZKEPA To Reduce Cardiovascular Events In High-Risk Statin-Treated Adults

Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 150 percent decrease over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $56.519 million which missed the analyst consensus estimate of $57.045 million by 0.92 percent. This is a 34.26 percent decrease over sales of $85.975 million the same period last year.

Amarin Corp Q1 2024 Adj EPS $(0.01) Beats $(0.03) Estimate, Sales $56.519M Miss $57.045M Estimate

<h3>Gainers</h3>
<ul>
<li>Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) stock rose 12.3% to $10.67 during Wednesday's after-market session. The market value of their outstanding shares is at $329.4 million. </li>
<li>Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) stock moved upwards by 8.12% to $0.95. The company's market cap stands at $381.2 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock rose 7.47% to $2.3. The market value of their outstanding shares is at $8.3 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) shares moved upwards by 7.14% to $0.34. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares moved upwards by 7.12% to $0.34. The company's market cap stands at $10.3 million. </li>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) shares moved upwards by 6.98% to $0.49. The market value of their outstanding shares is at $23.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) shares decreased by 11.3% to $0.22 during Wednesday's after-market session. The company's market cap stands at $17.2 million. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) shares fell 5.24% to $0.32. The company's market cap stands at $17.7 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock fell 4.84% to $0.55. The company's market cap stands at $13.1 million. </li>
<li>Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) shares decreased by 3.68% to $0.28. The company's market cap stands at $27.7 million. </li>
<li>Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) stock fell 3.6% to $2.68. The company's market cap stands at $375.8 million. </li>
<li>Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) shares fell 3.49% to $88.02. The market value of their outstanding shares is at $16.7 billion. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRV

AKLI

BMRN

CPHI

DARE

MREO

ONMD

PHGE

TBIO

12 Health Care Stocks Moving In Wednesday's After-Market Session

Press Releases

HLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug Plan

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Amarin Announces Two Upcoming Investor Events

Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update

Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association's (AHA) Annual Scientific Sessions

Amarin Appoints Peter Fishman Chief Financial Officer

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Comments

Amarin Corp

Noticias

Últimas noticias sobre Amarin Corp (NASDAQ:AMRN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL